Abstract
TED, an autoimmune, inflammatory disease, is characterized by retro-orbital tissue expansion and devastating changes in facial appearance and visual function. The Graves’ Ophthalmopathy QOL (GO-QOL) questionnaire is TED specific but has not been mapped to health state utility (HSU) scores. Recently, mean score for moderate-severe TED was assessed as 0.44. To quantify QALY improvements with teprotumumab, we correlated and bridged GO-QOL values with TTO-derived utility scores.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
